Inspire Medical Systems (NYSE:INSP - Get Free Report) had its target price reduced by equities researchers at Robert W. Baird from $252.00 to $248.00 in a report released on Tuesday,Benzinga reports. The firm currently has an "outperform" rating on the stock. Robert W. Baird's price objective would suggest a potential upside of 33.87% from the company's current price.
Several other research firms also recently weighed in on INSP. Bank of America raised shares of Inspire Medical Systems from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $220.00 to $255.00 in a report on Wednesday, November 20th. KeyCorp reaffirmed an "overweight" rating and issued a $234.00 price objective (down previously from $236.00) on shares of Inspire Medical Systems in a report on Friday, January 24th. Stifel Nicolaus reduced their price objective on shares of Inspire Medical Systems from $200.00 to $190.00 and set a "hold" rating for the company in a report on Tuesday, January 21st. Royal Bank of Canada reiterated an "outperform" rating and issued a $260.00 price target on shares of Inspire Medical Systems in a research report on Tuesday, November 5th. Finally, Wells Fargo & Company dropped their price target on shares of Inspire Medical Systems from $198.00 to $195.00 and set an "equal weight" rating on the stock in a research report on Tuesday. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $228.82.
Read Our Latest Report on Inspire Medical Systems
Inspire Medical Systems Trading Down 1.0 %
INSP stock traded down $1.90 during trading on Tuesday, hitting $185.25. The company had a trading volume of 379,947 shares, compared to its average volume of 615,460. The firm has a market capitalization of $5.55 billion, a price-to-earnings ratio of 172.43 and a beta of 1.32. The business has a 50 day moving average of $189.11 and a 200 day moving average of $191.33. Inspire Medical Systems has a fifty-two week low of $123.00 and a fifty-two week high of $257.40.
Inspire Medical Systems (NYSE:INSP - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.41. Inspire Medical Systems had a net margin of 4.37% and a return on equity of 5.30%. As a group, equities analysts predict that Inspire Medical Systems will post 1.33 EPS for the current year.
Insiders Place Their Bets
In other Inspire Medical Systems news, CTO John Rondoni sold 583 shares of the business's stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $170.49, for a total transaction of $99,395.67. Following the sale, the chief technology officer now owns 10,424 shares in the company, valued at approximately $1,777,187.76. The trade was a 5.30 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 4.10% of the company's stock.
Institutional Trading of Inspire Medical Systems
Institutional investors and hedge funds have recently bought and sold shares of the stock. Creative Planning grew its stake in Inspire Medical Systems by 12.4% during the 2nd quarter. Creative Planning now owns 2,575 shares of the company's stock valued at $345,000 after acquiring an additional 284 shares in the last quarter. GAMMA Investing LLC grew its stake in Inspire Medical Systems by 559.3% during the 3rd quarter. GAMMA Investing LLC now owns 178 shares of the company's stock valued at $38,000 after acquiring an additional 151 shares in the last quarter. CWM LLC grew its stake in Inspire Medical Systems by 550.5% during the 3rd quarter. CWM LLC now owns 8,105 shares of the company's stock valued at $1,711,000 after acquiring an additional 6,859 shares in the last quarter. Exchange Traded Concepts LLC purchased a new position in Inspire Medical Systems during the 3rd quarter valued at about $100,000. Finally, nVerses Capital LLC grew its stake in Inspire Medical Systems by 18.8% during the 3rd quarter. nVerses Capital LLC now owns 1,900 shares of the company's stock valued at $401,000 after acquiring an additional 300 shares in the last quarter. Institutional investors and hedge funds own 94.91% of the company's stock.
Inspire Medical Systems Company Profile
(
Get Free Report)
Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.
Featured Stories
Before you consider Inspire Medical Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inspire Medical Systems wasn't on the list.
While Inspire Medical Systems currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
